Last week we published Post-ASCO QuickPoll data in melanoma, and now this week we’ll explore another important tumor type – GU cancers. QuickPolls are a first glimpse into physicians’ reactions to new data presented at ASCO ’11. OBR and MDoutlook are pleased to share results from MDoutlook’s 4th annual post-ASCO survey fielded among its global network of 52,000 cancer physicians.
Quick Poll Methodology and Respondents’ Geographic Distribution
1) Axitinib is Expected to Have a High Impact on the Clinical Practice for Metastatic Renal Cell Carcinoma
2) Axitinib Will be Widely Used in Metastatic Renal Cell Carcinoma Following Treatment with Sunitinib
3) Increasing Usage of Intermittent Androgen Suppression Upon Rising PSA Levels
4) Abiraterone and Cabazitaxel are Seen as the Most Valuable New Therapeutics for Prostate Cancer
Quick polls are a fast way of measuring expected acceptance of clinical data post major medical meetings, and perhaps can be used to make some assumptions about adoption amongst providers. In today’s information hungry environment, the speed at which these polls can be conducted and analyzed can be advantageous for market planning and “pressure testing” acceptance of data amongst key stakeholders.